Press Releases

October 8, 2020 – Oligomerix Relocates Headquarters to Accommodate Growth

September 15, 2020 – Oligomerix Receives $3.19 Million NIH Commercialization Readiness Pilot Grant for Alzheimer’s Disease Therapy

July 23, 2020 – Oligomerix to Present at AAIC 2020 Conference on Small Molecule Inhibitor of Tau Self-Association

May 20, 2020 – Oligomerix Appoints William Erhardt, M.D., as Chief Medical Officer

May 8, 2020 – Oligomerix Announces Appointment of Robert Foerster, Former Pfizer Executive, as Chief Financial Officer

February 12, 2020 – Oligomerix Presents Preclinical Data at TAU2020 Global Conference for Small Molecule Inhibitor of Tau Self-Association

February 6, 2020 – Oligomerix to Present at BIO CEO & Invester Conference, Tau2020 Global Conference

November 22, 2019 – Newly Discovered Drug Is Able To Inhibit Neurotoxic Tau Oligomers In Brains, Paving The Way For A Potential Cure for Alzheimer

November 19, 2019 – Oligomerix and Feinstein Institutes Publish In Vivo Alzheimer’s Disease Treatment Data

October 10, 2019 – Oligomerix Awarded $2.18 Million SBIR Grant for Tau Oligomer Inhibitor for Alzheimer’s Disease and Related Disorders

June 3, 2019 – Oligomerix Receives Ongoing Support from NIH and Moves Forward with IND-enabling Studies

May 30, 2019 – Oligomerix to Participate in the NIH Innovation Zone at 2019 BIO International Convention

October 17, 2018 – Oligomerix Awarded 1.98 Million NIH SBIR-Phase IIb Grant

October 8, 2018 – Oligomerix Relocates to Albert Einstein College of Medicine Campus

October 1, 2018 – Oligomerix Inc. Awarded 2.49 Million Fast-Track

September 7, 2017 – Oligomerix, Inc. Awarded National Institute on Aging SBIR Grant for Development of Alzheimer’s Disease Specific Biomarker

May 2, 2016 – Oligomerix Awarded a Grant for its Alzheimer’s Drug Discovery Program Targeting Tau Oligomers from the National Institutes of Health

January 3, 2014 – Oligomerix to Present at Biotech Showcase^TM 2014

December 9, 2013 – Taconic and Oligomerix to Collaborate on Tau Mouse Model Characterization for Use in Alzheimer’s Disease Research

December 4, 2013 – Identification of a Tau Oligomer Structure That is Toxic to Neurons

September 10, 2013 – Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimer’s Disease Progression

July 8, 2013 – Oligomerix, Inc. to Present Multiple Posters Highlighting its Tau-Focused Technology During the Annual Alzheimer’s Association International Conference

May 22, 2013 – Oligomerix, Inc. Completes Series B Financing

April 23, 2012 – Oligomerix, Inc. Completes $2 Million Series A Financing

November 16, 2010 – SFN 2010 Press Release: Validation of Extracellular Tau Oligomer Target

November 11, 2010 – Oligomerix Awarded Phase II NIH Grant to Discover Novel Drugs for Alzheimer’s Disease

October 13, 2010 – Oligomerix Announces Board Changes: Vic Micati Appointed Chairman and Jack Pasini Appointed Company Director and Chief Commercial Officer

February 24, 2009 – Oligomerix Awarded NIH Grant to Develop Novel Biomarkers for Alzheimer’s Disease

July 7, 2008 – Oligomerix funded by the Alzheimer’s Drug Discovery Foundation to evaluate compounds active against tau oligomers, a novel target for therapeutic development

August 8, 2007 – Victor P. Micati Joins OLIGOMERIX’s Board of Directors

May 2, 2007 – Oligomerix Awarded NIH Grant to Develop Novel Drug Discovery Technology for Alzheimer’s Disease